Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses

• DOI: 10.1007/s13555-019-00337-y
• Publication Date: 2019-11-04T09:03:03Z
• Authors: Richard B. Warren; Kyoungah See; Russel Burge; Ying Zhang; Alan Brnabic; Gaia Gallo; Alyssa Garrelts; Alexander Egeberg
• Keywords: Ixekizumab; Ustekinumab; Golimumab; Certolizumab pegol

Rapid improvement of psoriasis is valued by patients and should be considered to an important factor in treatment selection. We investigated Psoriasis Area Severity Index (PASI) Dermatology Life Quality (DLQI) response rates within the first 12 weeks compare rapid 11 biologic therapies for moderate-to-severe using Bayesian Frequentist network meta-analyses (NMA). A systematic literature review was conducted identify phase 3, double-blind, randomized, controlled trials adult with treated interleukin (IL)-17 (brodalumab, ixekizumab, secukinumab), IL-12/-23 (ustekinumab), IL-23 (guselkumab, risankizumab, tildrakizumab), or tumor necrosis inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab). Outcome measures extracted from 32 publications were ≥ 75, 90, 100% PASI score (PASI 100, respectively) at 2, 4, 8, DLQI (0,1), where (0,1) indicates no effect on patient's life, week 12. NMA (BNMA) used fixed-treatment random-baseline effect, normal independent models. (fNMA) as sensitivity analyses test robustness findings. Based BNMA fNMA, brodalumab ixekizumab showed most effects 75 8 90 100 12; overlapped risankizumab Brodalumab, secukinumab yielded higher gains compared all other biologics studied. Additional quality life not assessed this report. Ixekizumab provide earliest clinical benefit 2 among studied, including treatments such secukinumab, ustekinumab, guselkumab, adalimumab, etanercept. fNMA results similar relative estimates rankings. Eli Lilly Company.